Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add DaVita (DVA) to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care raises optimism about the stock.

Masimo (MASI) Gets Non-Binding Offer for Consumer Business

by Zacks Equity Research

Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.

GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment

by Zacks Equity Research

GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

by Zacks Equity Research

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

by Zacks Equity Research

IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now

by Zacks Equity Research

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance

by Zacks Equity Research

Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

by Zacks Equity Research

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

by Zacks Equity Research

The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.

Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod

by Zacks Equity Research

Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.

Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?

by Zacks Equity Research

Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.

Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall

by Zacks Equity Research

Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure

Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital

by Zacks Equity Research

Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.

Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now

by Zacks Equity Research

BD's (BDX) robust product portfolio raises optimism about the stock.

Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board

by Zacks Equity Research

Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.

DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs

by Zacks Equity Research

Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.

Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial

by Zacks Equity Research

Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.

Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes

by Zacks Equity Research

Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.

Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data

by Zacks Equity Research

Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.

KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan

by Zacks Equity Research

KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.